184 related articles for article (PubMed ID: 10485918)
1. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor.
Doherty JK; Bond C; Jardim A; Adelman JP; Clinton GM
Proc Natl Acad Sci U S A; 1999 Sep; 96(19):10869-74. PubMed ID: 10485918
[TBL] [Abstract][Full Text] [Related]
2. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.
Azios NG; Romero FJ; Denton MC; Doherty JK; Clinton GM
Oncogene; 2001 Aug; 20(37):5199-209. PubMed ID: 11526509
[TBL] [Abstract][Full Text] [Related]
3. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation.
Aigner A; Juhl H; Malerczyk C; Tkybusch A; Benz CC; Czubayko F
Oncogene; 2001 Apr; 20(17):2101-11. PubMed ID: 11360194
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin.
Xu FJ; Boyer CM; Bae DS; Wu S; Greenwald M; O'Briant K; Yu YH; Mills GB; Bast RC
Int J Cancer; 1994 Oct; 59(2):242-7. PubMed ID: 7927925
[TBL] [Abstract][Full Text] [Related]
5. Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinases.
Park BW; O'Rourke DM; Wang Q; Davis JG; Post A; Qian X; Greene MI
Proc Natl Acad Sci U S A; 1999 May; 96(11):6434-8. PubMed ID: 10339605
[TBL] [Abstract][Full Text] [Related]
6. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.
Christianson TA; Doherty JK; Lin YJ; Ramsey EE; Holmes R; Keenan EJ; Clinton GM
Cancer Res; 1998 Nov; 58(22):5123-9. PubMed ID: 9823322
[TBL] [Abstract][Full Text] [Related]
7. Receptor binding specificities of Herstatin and its intron 8-encoded domain.
Shamieh LS; Evans AJ; Denton MC; Clinton GM
FEBS Lett; 2004 Jun; 568(1-3):163-6. PubMed ID: 15196940
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
9. Herstatin, an autoinhibitor of the human epidermal growth factor receptor 2 tyrosine kinase, modulates epidermal growth factor signaling pathways resulting in growth arrest.
Justman QA; Clinton GM
J Biol Chem; 2002 Jun; 277(23):20618-24. PubMed ID: 11934884
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.
Zhang L; Lau YK; Xi L; Hong RL; Kim DS; Chen CF; Hortobagyi GN; Chang C; Hung MC
Oncogene; 1998 Jun; 16(22):2855-63. PubMed ID: 9671406
[TBL] [Abstract][Full Text] [Related]
11. Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer.
Valerón PF; Chirino R; Fernandez L; Torres S; Navarro D; Aguiar J; Cabrera JJ; Diaz-Chico BN; Diaz-Chico JC
Int J Cancer; 1996 Jan; 65(2):129-33. PubMed ID: 8567106
[TBL] [Abstract][Full Text] [Related]
12. Expression of the c-erbB-2-encoded oncoprotein p185 (HER-2/neu) in pregnancy as a model for oncogene-induced carcinogenesis.
Mielke S; Meden H; Kuhn W
Med Hypotheses; 1998 May; 50(5):359-62. PubMed ID: 9681912
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells.
Marth C; Lang T; Cronauer MV; Doppler W; Zeimet AG; Bachmair F; Ullrich A; Daxenbichler G
Int J Cancer; 1992 Sep; 52(2):311-6. PubMed ID: 1355758
[TBL] [Abstract][Full Text] [Related]
14. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.
Scott GK; Robles R; Park JW; Montgomery PA; Daniel J; Holmes WE; Lee J; Keller GA; Li WL; Fendly BM
Mol Cell Biol; 1993 Apr; 13(4):2247-57. PubMed ID: 8096058
[TBL] [Abstract][Full Text] [Related]
15. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells.
Lin YZ; Clinton GM
Oncogene; 1991 Apr; 6(4):639-43. PubMed ID: 1674366
[TBL] [Abstract][Full Text] [Related]
16. [Effect of trastuzumab on tumor cell lines shedding high or low level of HER-2 ECD].
Liu CY; Yang W; Li JF; Sun SL; Shou CC
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):101-5. PubMed ID: 17645842
[TBL] [Abstract][Full Text] [Related]
17. p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression.
Xie Y; Hung MC
Biochem Biophys Res Commun; 1996 Apr; 221(1):140-5. PubMed ID: 8660324
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.
Zhang L; Hung MC
Oncogene; 1996 Feb; 12(3):571-6. PubMed ID: 8637714
[TBL] [Abstract][Full Text] [Related]
19. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
20. In vivo identification of the interaction site of ErbB2 extracellular domain with its autoinhibitor.
Hu P; Feng J; Zhou T; Wang J; Jing B; Yu M; Hu M; Zhang X; Shen B; Guo N
J Cell Physiol; 2005 Dec; 205(3):335-43. PubMed ID: 15920761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
